Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

National Cancer Center Hospital East clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Japan register with National Cancer Center Hospital East as lead sponsor. Synced 16 Nov 2026
8Current trials
4Recruiting now
11Drugs in these trials
1Trial register
At a glance

National Cancer Center Hospital East is the lead sponsor of 8 current clinical trials in our Japan register. 4 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Pembrolizumab, Docetaxel and Fluorouracil. The most-studied condition is Non-small Cell Lung Cancer Stage IB.

ClinicalTrials.gov trials by status

  • Recruiting450%
  • Active, closed450%

Trials by phase

  • Phase 2675%
  • Phase 3225%
01

Clinical trials sponsored by National Cancer Center Hospital East

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
NCT07018570 · ClinicalTrials.gov ↗ · Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2 Recruiting 2025-07 Japan
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
NCT04288999 · Rectal Cancer Recurrent
Phase 3 Recruiting 2019-10 Japan
Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab
NCT07100704 · Recurrent/ Metastatic Olfactory Neuroblastoma
Drug: Nivolumab
Phase 2 Recruiting 2025-04 Japan
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
NCT05646511 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer
Drug: Folfox
Phase 3 Recruiting 2022-11 Japan
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
NCT04040361 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
Phase 2 Active, closed 2019-11 Japan
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
NCT04745988 · ClinicalTrials.gov ↗ · Gastric Cancer
Phase 2 Active, closed 2021-11 Japan
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
NCT05696548 · ClinicalTrials.gov ↗ · Anaplastic Thyroid Cancer
Phase 2 Active, closed 2019-07 Japan
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
NCT05034887 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 2 Active, closed 2022-01 Japan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in National Cancer Center Hospital East trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in National Cancer Center Hospital East trials

11 conditions
Non-small Cell Lung Cancer Stage IB1Non-small Cell Lung Cancer Stage II1Non-small Cell Lung Cancer Stage ⅢA1Gastroesophageal Junction (GEJ) Adenocarcinoma1Gastric Cancer1Anaplastic Thyroid Cancer1Rectal Cancer Recurrent1Gastric Adenocarcinoma1Gastroesophageal Junction Adenocarcinoma1Recurrent/ Metastatic Olfactory Neuroblastoma1Locally Advanced Rectal Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Japan84

A trial with sites in more than one country appears in each of those registers.

05

Questions about National Cancer Center Hospital East trials

How many clinical trials does National Cancer Center Hospital East sponsor?

National Cancer Center Hospital East is the lead sponsor of 8 current trials on ClinicalTrials.gov in our Japan register, as of the registry sync on 16 November 2026. Completed and withdrawn studies are not counted.

Are National Cancer Center Hospital East trials recruiting?

Yes. 4 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is National Cancer Center Hospital East testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are Pembrolizumab (3), Docetaxel (2), Fluorouracil (2), Lenvatinib (2) and Levofolinate (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 16 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.